Patent ID: 11957729
Assignee: IMMATICS BIOTECHNOLOGIES GMBH
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 2:
3. The method of claim 2, wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide coglycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.